Production (Stage)
Compass Therapeutics, Inc.
CMPX
$2.38
-$0.035-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 38.91% | -2.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.40% | 35.42% | |||
| Operating Income | -8.40% | -35.42% | |||
| Income Before Tax | -10.64% | -43.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.64% | -43.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.64% | -43.43% | |||
| EBIT | -8.40% | -35.42% | |||
| EBITDA | -8.47% | -35.86% | |||
| EPS Basic | -9.36% | -44.36% | |||
| Normalized Basic EPS | -9.30% | -44.54% | |||
| EPS Diluted | -9.36% | -44.36% | |||
| Normalized Diluted EPS | -9.30% | -44.54% | |||
| Average Basic Shares Outstanding | 1.18% | -0.70% | |||
| Average Diluted Shares Outstanding | 1.18% | -0.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||